- Home
- PHAT vs NAK Comparison
PHAT vs NAK Comparison
Compare PHAT & NAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- NAK
- Stock Information
- Founded
- PHAT 2018
- NAK 1983
- Country
- PHAT United States
- NAK Canada
- Employees
- PHAT N/A
- NAK N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- NAK Precious Metals
- Sector
- PHAT Health Care
- NAK Basic Materials
- Exchange
- PHAT Nasdaq
- NAK Nasdaq
- Market Cap
- PHAT 942.6M
- NAK 922.7M
- IPO Year
- PHAT 2019
- NAK 2002
- Fundamental
- Price
- PHAT $14.85
- NAK $1.62
- Analyst Decision
- PHAT Strong Buy
- NAK Strong Buy
- Analyst Count
- PHAT 5
- NAK 2
- Target Price
- PHAT $17.60
- NAK $2.50
- AVG Volume (30 Days)
- PHAT 983.2K
- NAK 8.8M
- Earning Date
- PHAT 10-30-2025
- NAK 11-13-2025
- Dividend Yield
- PHAT N/A
- NAK N/A
- EPS Growth
- PHAT N/A
- NAK N/A
- EPS
- PHAT N/A
- NAK N/A
- Revenue
- PHAT $147,190,000.00
- NAK N/A
- Revenue This Year
- PHAT $218.38
- NAK N/A
- Revenue Next Year
- PHAT $87.14
- NAK N/A
- P/E Ratio
- PHAT N/A
- NAK N/A
- Revenue Growth
- PHAT 460.30
- NAK N/A
- 52 Week Low
- PHAT $2.21
- NAK $0.44
- 52 Week High
- PHAT $16.08
- NAK $2.98
- Technical
- Relative Strength Index (RSI)
- PHAT 64.62
- NAK 42.29
- Support Level
- PHAT $14.12
- NAK $1.56
- Resistance Level
- PHAT $15.28
- NAK $1.91
- Average True Range (ATR)
- PHAT 0.93
- NAK 0.13
- MACD
- PHAT 0.07
- NAK -0.05
- Stochastic Oscillator
- PHAT 82.58
- NAK 13.54
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About NAK Northern Dynasty Minerals Ltd.
Northern Dynasty Minerals Ltd is a mineral exploration company. It has a single operating segment of acquisition, exploration, and development of mineral properties. Its core asset is the Pebble Project located in Alaska, USA. The Pebble project is seeking to develop a deposit of copper, gold, molybdenum, and silver into a modern mining operation.